Search alternatives:
large decrease » larger decrease (Expand Search), marked decrease (Expand Search), large increases (Expand Search)
means decrease » mean decrease (Expand Search), deaths decreased (Expand Search)
step decrease » sizes decrease (Expand Search), teer decrease (Expand Search), we decrease (Expand Search)
a large » _ large (Expand Search)
5 means » _ means (Expand Search), k means (Expand Search), i means (Expand Search)
Showing 1 - 20 results of 12,260 for search '(( a large decrease ) OR ((( 5 means decrease ) OR ( _ ((system decrease) OR (step decrease)) ))))', query time: 0.73s Refine Results
  1. 1
    Table of step height.

    Table of step height. by Jianbo Jia (717814)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  2. 2
    The well wall step.

    The well wall step. by Jianbo Jia (717814)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  3. 3
    LBM-based approach using synchronous transformation with a time step of 0.43s, PNGM-based method using asynchronous transformation with a 5s time step, VGA using explicit scheme with a 0.1s time step and asynchronous transformation with a 0.43s time step.

    LBM-based approach using synchronous transformation with a time step of 0.43s, PNGM-based method using asynchronous transformation with a 5s time step, VGA using explicit scheme wi... by Mouad Klai (20818364)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  4. 4
    Effective contact rate over time for the different modelling scenarios considered: fixed, continuously increasing, continuously decreasing and with a step-decrease.

    Effective contact rate over time for the different modelling scenarios considered: fixed, continuously increasing, continuously decreasing and with a step-decrease. by Joshua Looker (21390948)

    Published 2025
    “…<p>Effective contact rate over time for the different modelling scenarios considered: fixed, continuously increasing, continuously decreasing and with a step-decrease.</p>…”
    Save to List
    Saved in:
  5. 5
    Comparison of diffusion simulations: implicit scheme of the GDE with a 30-second time step (blue line), implicit scheme of the PNGM with α = 0.6 and a 15-second time step (green line), and LBM with a 0.43-second time step (red line).

    Comparison of diffusion simulations: implicit scheme of the GDE with a 30-second time step (blue line), implicit scheme of the PNGM with α = 0.6 and a 15-second time step (green li... by Mouad Klai (20818364)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  6. 6
    Study Flow Diagram.

    Study Flow Diagram. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  7. 7
    Antibody and antigen responses to Lufotrelvir vs placebo day 1–90.

    Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  8. 8
    Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments).

    Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  9. 9
    Antibody and antigen responses to Ensovibep vs placebo day 1–90.

    Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  10. 10
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  11. 11
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  12. 12
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  13. 13
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  14. 14
    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis).

    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  15. 15
    Long-term anti-nucleocapsid response by baseline patient characteristics.

    Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  16. 16
    Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity.

    Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  17. 17
    Baseline patient characteristics across neutralizing monoclonal antibody trials.

    Baseline patient characteristics across neutralizing monoclonal antibody trials. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  18. 18
    Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies.

    Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  19. 19
    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis).

    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  20. 20
    Overview of the six original ACTIV-3/TICO trials.

    Overview of the six original ACTIV-3/TICO trials. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:

Search Tools: